Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Monoclonal antibody levels and protection from COVID-19
Eva Stadler, Martin Burgess, Timothy E. Schlub, et al.
Nature Communications (2023) Vol. 14, Iss. 1
Open Access | Times Cited: 31

Showing 1-25 of 31 citing articles:

Predicting vaccine effectiveness for mpox
Matthew T. Berry, Shanchita R. Khan, Timothy E. Schlub, et al.
Nature Communications (2024) Vol. 15, Iss. 1
Open Access | Times Cited: 21
Efficacy and safety of sipavibart for prevention of COVID-19 in individuals who are immunocompromised (SUPERNOVA): a randomised, controlled, double-blind, phase 3 trial
Ghady Haidar, S. Thomas, Paul Loubet, et al.
The Lancet Infectious Diseases (2025)
Closed Access | Times Cited: 1
COVID-19 therapeutics
Daniele Focosi, Massimo Franchini, Fabrizio Maggi, et al.
Clinical Microbiology Reviews (2024) Vol. 37, Iss. 2
Closed Access | Times Cited: 10
Risk of SARS-CoV-2 infection and adverse outcomes among vaccinated patients with tuberculosis
Renin Chang, Sheng-Yin Chen, Tina Yi Jin Hsieh, et al.
Public Health (2025) Vol. 239, pp. 80-86
Closed Access
SA55 broadly neutralizes SARS-CoV-2 and robustly prevents viral escape by JN.1 sublineages
Longqing Shi, Anthony Bowen, Juan Han, et al.
bioRxiv (Cold Spring Harbor Laboratory) (2025)
Closed Access
Prevention and management of infectious complications in patients with chronic lymphocytic leukemia (CLL) treated with BTK and BCL-2 inhibitors, focus on current guidelines
Małgorzata Mikulska, Chiara Oltolini, Emanuela Zappulo, et al.
Blood Reviews (2024) Vol. 65, pp. 101180-101180
Open Access | Times Cited: 4
Accelerating therapeutics development during a pandemic: population pharmacokinetics of the long-acting antibody combination AZD7442 (tixagevimab/cilgavimab) in the prophylaxis and treatment of COVID-19
Lindsay E. Clegg, Oleg Stepanov, Henning Schmidt, et al.
Antimicrobial Agents and Chemotherapy (2024) Vol. 68, Iss. 5
Open Access | Times Cited: 4
A spike virosome vaccine induces pan-sarbecovirus antibody responses in mice
Mitch Brinkkemper, Meliawati Poniman, Esther Siteur-van Rijnstra, et al.
iScience (2024) Vol. 27, Iss. 5, pp. 109719-109719
Open Access | Times Cited: 4
Single Monoclonal Antibodies Should Not Be Used for Coronavirus Disease 2019 Therapy: A Call for Antiviral Stewardship
Arturo Casadevall, Daniele Focosi, Liise-anne Pirofski, et al.
Clinical Infectious Diseases (2024) Vol. 79, Iss. 6, pp. 1404-1407
Closed Access | Times Cited: 4
Immunobridging for Pemivibart, a Monoclonal Antibody for Prevention of Covid-19
Peter Schmidt, Yong Li, Myra Popejoy
New England Journal of Medicine (2024) Vol. 391, Iss. 19, pp. 1860-1862
Open Access | Times Cited: 4
Monkeypox: A comprehensive review on mutation, transmission, pathophysiology, and therapeutics
Somenath Dutta, Rohan Ghosh, I. Dasgupta, et al.
International Immunopharmacology (2024) Vol. 146, pp. 113813-113813
Closed Access | Times Cited: 4
The Ambivalence of Post COVID-19 Vaccination Responses in Humans
Radha Gopalaswamy, Vivekanandhan Aravindhan, Selvakumar Subbian
Biomolecules (2024) Vol. 14, Iss. 10, pp. 1320-1320
Open Access | Times Cited: 3
A Web Tool to Estimate Baseline Anti-Spike Monoclonal Antibody Efficacy Based on Regional Genomic Surveillance
Daniele Focosi
Viruses (2023) Vol. 15, Iss. 5, pp. 1048-1048
Open Access | Times Cited: 9
Microfluidic-assisted single-cell RNA sequencing facilitates the development of neutralizing monoclonal antibodies against SARS-CoV-2
Ziwei Wang, Amelia Siqi Huang, Lingfang Tang, et al.
Lab on a Chip (2024) Vol. 24, Iss. 4, pp. 642-657
Open Access | Times Cited: 2
Star-polymers as potent broad-spectrum extracellular virucidal antivirals
Elana H. Super, Si Min Lai, Urszula Cytlak-Chaudhuri, et al.
bioRxiv (Cold Spring Harbor Laboratory) (2024)
Closed Access | Times Cited: 2
A ferritin-based COVID-19 nanoparticle vaccine that elicits robust, durable, broad-spectrum neutralizing antisera in non-human primates
Payton A. Weidenbacher, Mrinmoy Sanyal, Natalia Friedland, et al.
bioRxiv (Cold Spring Harbor Laboratory) (2022)
Open Access | Times Cited: 9
Upregulation of key factors of viral entry of corona‐ and influenza viruses upon TLR3‐signaling in cells from the respiratory tract and clinical treatment options by 1,8‐Cineol
Leonie Hose, Matthias Schürmann, Holger Sudhoff
Phytotherapy Research (2024) Vol. 38, Iss. 9, pp. 4453-4466
Open Access | Times Cited: 1
An overview of the development of pharmacotherapeutics targeting SARS-CoV-2
Tom Lucaj, Ian Hay, Amirreza Samarbakhsh, et al.
Drug Discovery Today (2024) Vol. 29, Iss. 9, pp. 104126-104126
Closed Access | Times Cited: 1
2024 Clinical Practice Guideline Update by the Infectious Diseases Society of America on the Management of COVID-19: Anti-SARS-CoV-2 Neutralizing Antibody Pemivibart for Pre-exposure Prophylaxis
Adarsh Bhimraj, Yngve Falck–Ytter, A. Y. Kim, et al.
Clinical Infectious Diseases (2024)
Closed Access | Times Cited: 1
Early antiviral CD4+ and CD8+ T cells are associated with upper airway clearance of SARS-CoV-2
Sydney I. Ramirez, Paul Lopez, Farhoud Faraji, et al.
JCI Insight (2024) Vol. 9, Iss. 24
Open Access | Times Cited: 1
Fc-mediated functions and the treatment of severe respiratory viral infections with passive immunotherapy – a balancing act
Hillary A. Vanderven, Stephen J. Kent
Frontiers in Immunology (2023) Vol. 14
Open Access | Times Cited: 4
Serum AZD7442 (tixagevimab–cilgavimab) concentrations and in vitroIC50 values predict SARS‐CoV‐2 neutralising antibody titres
Lindsay E. Clegg, Oleg Stepanov, Samuel A. Matthews, et al.
Clinical & Translational Immunology (2024) Vol. 13, Iss. 6
Open Access | Times Cited: 1
Early antiviral CD4 and CD8 T cell responses and antibodies are associated with upper respiratory tract clearance of SARS-CoV-2
Sydney I. Ramirez, Paul Lopez, Farhoud Faraji, et al.
bioRxiv (Cold Spring Harbor Laboratory) (2023)
Open Access | Times Cited: 2
A tetravalent bispecific antibody outperforms the combination of its parental antibodies and neutralizes diverse SARS-CoV-2 variants
Abhishek Chiyyeadu, Girmay Asgedom, Matthias Bruhn, et al.
Clinical Immunology (2024) Vol. 260, pp. 109902-109902
Open Access
A cross-sectional study of SARS-CoV-2 antibodies among healthcare workers in a tertiary care hospital in Taiwan: implications for protection against the Omicron variants
Chang‐Hua Chen, Day‐Yu Chao, Chew‐Teng Kor, et al.
BMC Infectious Diseases (2024) Vol. 24, Iss. 1
Open Access
Page 1 - Next Page

Scroll to top